Literature DB >> 16402392

Update on the molecular biology of mantle cell lymphoma.

Francesco Bertoni1, Andrea Rinaldi, Emanuele Zucca, Franco Cavalli.   

Abstract

Mantle cell lymphoma (MCL) accounts for 5-10% of non-Hodgkin's lymphomas and it bears the worst prognosis among B cell lymphomas. Even more than in the other lymphomas, new insights in MCL biology are needed. In this review we will discuss the most recent published data. Immunoglobulin sequencing data suggest that the MCL cell of origin is a mature B cell which might have undergone an extra-follicular T-cell independent antigen maturation. The main aberrations that affect cell cycle and DNA repair pathways in MCL are summarized, also discussing the need of the t(11;14)(q13;q32) to make diagnosis of MCL. After the gene expression studies of the last years, now the research focus has moved towards the new opportunities provided by arrayCGH technique for gene discovery and for identification of therapeutic targets. Examples of genes identified because deleted or amplified at DNA level and that might be relevant for MCL pathogenesis are presented. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2006        PMID: 16402392     DOI: 10.1002/hon.767

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  28 in total

Review 1.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

Review 2.  Cyclin D degradation by E3 ligases in cancer progression and treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  Semin Cancer Biol       Date:  2020-01-30       Impact factor: 15.707

3.  Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines.

Authors:  Katrin Tiemann; Jessica V Alluin; Anja Honegger; Pritsana Chomchan; Shikha Gaur; Yen Yun; Stephen J Forman; John J Rossi; Robert W Chen
Journal:  Leuk Lymphoma       Date:  2011-07-12

4.  Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.

Authors:  Matthew J Barth; Cory Mavis; Myron S Czuczman; Francisco J Hernandez-Ilizaliturri
Journal:  Clin Cancer Res       Date:  2015-05-11       Impact factor: 12.531

5.  Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

Authors:  A Goy; S H Bernstein; B S Kahl; B Djulbegovic; M J Robertson; S de Vos; E Epner; A Krishnan; J P Leonard; S Lonial; S Nasta; O A O'Connor; H Shi; A L Boral; R I Fisher
Journal:  Ann Oncol       Date:  2008-12-12       Impact factor: 32.976

Review 6.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

7.  Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.

Authors:  Rekha Rao; Pearl Lee; Warren Fiskus; Yonghua Yang; Rajeshree Joshi; Yongchao Wang; Kate Buckley; Ramesh Balusu; Jianguang Chen; Sanjay Koul; Atul Joshi; Sunil Upadhyay; Jianguo Tao; Eduardo Sotomayor; Kapil N Bhalla
Journal:  Cancer Biol Ther       Date:  2009-07       Impact factor: 4.742

8.  Cyclin D1 expression in peripheral T-cell lymphomas.

Authors:  Joo Y Song; Liping Song; Alex F Herrera; Girish Venkataraman; Joyce L Murata-Collins; Victoria H Bedell; Yuan Yuan Chen; Young S Kim; Reda Tadros; Bharat N Nathwani; Dennis D Weisenburger; Andrew L Feldman
Journal:  Mod Pathol       Date:  2016-07-29       Impact factor: 7.842

9.  Gastrointestinal B-cell lymphomas: From understanding B-cell physiology to classification and molecular pathology.

Authors:  Xavier Sagaert; Thomas Tousseyn; Rhonda K Yantiss
Journal:  World J Gastrointest Oncol       Date:  2012-12-15

10.  Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.

Authors:  Hyun Joo Jung; Zheng Chen; Nami McCarty
Journal:  Am J Hematol       Date:  2012-09-11       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.